These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance
Even the launch of generic versions of heart failure blockbuster Entresto and Trump's threats to cut drug prices won't overshadow the strong performance of Novartis AG's oncology franchise. So, sales of Scemblix, which is rapidly capturing the chronic myeloid leukemia market, reached $298 million for NVS in the second quarter of 2025, an increase of 81.7% year-on-year. Also, I was pleased to see that NVS repurchased $2.71 billion worth of its shares in Q2 2025, a 68% increase year-on-year.
US FDA approves Novartis' drug for skin disease
The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the company said on Tuesday.
Novartis has stockpiles to withstand potential Trump tariffs, CEO says
Novartis has increased its stockpiles of pharmaceuticals in the United States and is well prepared should its products be hit by President Donald Trump's tariffs, its chief executive said in an interview published on Saturday.
This Small Biotech Stock Is Surging Today. Here's Why.
Tourmaline Bio (TRML) shares have had a strong run this year. News that Swiss pharma giant Novartis (NVS) is buying the small biotech firm for $1.4 billion to complement its cardiovascular pipeline is giving Tourmaline a fresh boost.
Novartis: Pipeline Progress And Buyback Drive Upside
Novartis delivered strong Q2 results with 24% net income growth and robust sales from key drugs like Kisqali and Pluvicto, supporting our positive outlook. Despite generic competition and tariff concerns, Novartis' pipeline and US investment underpin our confidence. A $10 billion share buyback, higher guidance, and disciplined capital allocation further strengthen the Novartis investment case. We maintain our Buy rating.
Novartis's Ianalumab Meets Key Goal in Late-Stage Trials for Autoimmune Disease
The pharma company said the drug has the potential to become the first and only targeted treatment approved for patients with Sjoegren's disease.
Here's Why Novartis (NVS) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases.
Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price
Novartis AG delivered strong Q2 2025 results, outpacing expectations, but faces looming patent expiries for major drugs like Entresto, Tasigna, and Promacta. Growth in new and existing pipeline drugs, plus robust financials and buybacks, position Novartis for resilience despite upcoming revenue headwinds. While the company's long-term outlook remains positive, current valuation already reflects its strengths, making shares fairly valued at this time.
Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down
NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.
Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
